Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells 3,415 Shares

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Norbert Riedel sold 3,415 shares of the firm’s stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $192.00, for a total transaction of $655,680.00. Following the completion of the sale, the director directly owned 7,024 shares of the company’s stock, valued at approximately $1,348,608. The trade was a 32.71% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Jazz Pharmaceuticals Trading Up 0.2%

Shares of JAZZ stock traded up $0.44 on Monday, reaching $190.46. 725,871 shares of the company’s stock were exchanged, compared to its average volume of 1,139,967. The company’s fifty day simple moving average is $169.64 and its 200 day simple moving average is $151.92. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $198.00. The company has a current ratio of 1.86, a quick ratio of 1.67 and a debt-to-equity ratio of 1.00. The stock has a market capitalization of $11.72 billion, a PE ratio of -31.90, a P/E/G ratio of 0.38 and a beta of 0.22.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 earnings per share for the quarter, topping the consensus estimate of $6.49 by $0.15. The business had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.17 billion. Jazz Pharmaceuticals had a positive return on equity of 6.87% and a negative net margin of 8.35%.The business’s revenue for the quarter was up 8.1% compared to the same quarter last year. During the same period last year, the company earned $6.51 earnings per share. As a group, analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Institutional Trading of Jazz Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in JAZZ. Farther Finance Advisors LLC lifted its position in Jazz Pharmaceuticals by 754.8% during the third quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock valued at $35,000 after purchasing an additional 234 shares during the period. Hilltop National Bank purchased a new position in shares of Jazz Pharmaceuticals during the 4th quarter valued at about $36,000. Hantz Financial Services Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 471.4% in the 2nd quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock valued at $38,000 after buying an additional 297 shares during the period. LRI Investments LLC purchased a new stake in shares of Jazz Pharmaceuticals in the fourth quarter worth about $38,000. Finally, Danske Bank A S acquired a new stake in Jazz Pharmaceuticals during the third quarter worth about $40,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on JAZZ shares. Truist Financial boosted their price target on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a report on Monday, January 12th. TD Cowen reiterated a “buy” rating on shares of Jazz Pharmaceuticals in a report on Thursday, January 29th. Wells Fargo & Company increased their price target on Jazz Pharmaceuticals from $235.00 to $250.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. UBS Group restated a “neutral” rating and set a $188.00 price objective (up from $163.00) on shares of Jazz Pharmaceuticals in a report on Monday, November 24th. Finally, Wall Street Zen upgraded shares of Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Fourteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $214.57.

Key Stories Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Neutral Sentiment: Barclays initiated research coverage on Jazz, which typically increases analyst visibility and can boost trading interest, though the note’s tone and price targets will determine the directional impact. Jazz Pharmaceuticals (NASDAQ:JAZZ) Research Coverage Started at Barclays
• Neutral Sentiment: A Zacks piece highlights Jazz’s reliance on international sales and discusses how geographic mix and overseas growth patterns affect Street forecasts and revenue durability — a reminder that FX, pricing and market access abroad could swing future revenue and estimates. Jazz (JAZZ) Reliance on International Sales: What Investors Need to Know
• Negative Sentiment: EVP Neena M. Patil sold 55,600 shares on Feb. 26 at about $191.56 (~$10.65M), cutting her stake roughly in half — a large, high-dollar insider sale that may pressure sentiment. SEC Filing – Patil Sale
• Negative Sentiment: SVP Mary Elizabeth Henderson sold 5,343 shares on Feb. 26 at about $194.49 (~$1.04M), reducing her position by ~15.7% — another insider sell that could be viewed negatively by some investors. SEC Filing – Henderson Sale
• Negative Sentiment: CAO Patricia Carr executed two small sales (1,253 shares on Feb. 26 at ~$194.11 and 1,117 shares on Feb. 27 at ~$190.91), trimming her holdings by ~10–11% in each filing — smaller dollar amounts but consistent with the broader pattern of insider selling. SEC Filing – Carr Sales

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.